UB Paderborn / Katalog / Suche / in CDI

Mechanisms of Anesthetic Action and Neurotoxicity: Lessons from Molluscs

Frontiers in physiology, 2018-01, Vol.8, p.1138-1138

2018

Link zum Volltext

Verfügbarkeit prüfen

A novel bio-mimicking, planar nano-edge microelectrode enables enhanced long-term neural recording

Scientific reports, 2016-10, Vol.6 (1), p.34553-34553, Article 34553

2016

Link zum Volltext

Verfügbarkeit prüfen

The mitochondrial division inhibitor Mdivi-1 rescues mammalian neurons from anesthetic-induced cytotoxicity

Molecular brain, 2016-03, Vol.9 (1), p.35, Article 35

2016

Link zum Volltext

Verfügbarkeit prüfen

General anesthetics and cytotoxicity: possible implications for brain health

Drug and chemical toxicology (New York, N.Y. 1978), 2017-04, Vol.40 (2), p.241-249

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic Heart failure

Circulation (New York, N.Y.), 1999-12, Vol.100 (23), p.2312-2318

1999

Link zum Volltext

Verfügbarkeit prüfen

Acute coronary findings at autopsy in heart failure patients with sudden death : Results from the assessment of treatment with lisinopril and survival (ATLAS) trial

Circulation (New York, N.Y.), 2000-08, Vol.102 (6), p.611-616

2000

Link zum Volltext

Verfügbarkeit prüfen

Corrections needed to 2016 ESC and AHA guidelines on heart failure

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.325-326

2017

Link zum Volltext

Verfügbarkeit prüfen

Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

European heart journal, 2000-09, Vol.21 (18), p.1502-1513

2000

Link zum Volltext

Verfügbarkeit prüfen

Analyses of CCD images of nucleon-silicon interaction events

IEEE transactions on nuclear science, 2004-10, Vol.51 (5), p.2851-2856

2004

Link zum Volltext
IEEE_Xplore

Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction

Journal of the American College of Cardiology, 2000-09, Vol.36 (3), p.959-969

2000

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial

European heart journal, 2000-12, Vol.21 (23), p.1967-1978

2000

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

European heart journal, 2001-09, Vol.22 (17), p.1601-1612

2001

Link zum Volltext

Verfügbarkeit prüfen

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study

European journal of heart failure, 2000-12, Vol.2 (4), p.447-454

2000

Link zum Volltext

Verfügbarkeit prüfen

Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.325-326

2017

Link zum Volltext

Verfügbarkeit prüfen

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial

Journal of cardiac failure, 1998-03, Vol.4 (1), p.3-8

1998

Link zum Volltext

Verfügbarkeit prüfen

Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study

European journal of heart failure, 1999-03, Vol.1 (1), p.73-79

1999

Link zum Volltext

Verfügbarkeit prüfen

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group

European journal of heart failure, 2000-12, Vol.2 (4), p.447-454

2000

Link zum Volltext

Verfügbarkeit prüfen

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group

Circulation (New York, N.Y.), 1999-12, Vol.100 (23), p.2312-2318

1999

Link zum Volltext

Verfügbarkeit prüfen

Myocardial infarction redefined : A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

Clinical chemistry (Baltimore, Md.), 2001-03, Vol.47 (3), p.382-392

2001

Link zum Volltext

Verfügbarkeit prüfen

Scandinavian Colonialism and the Rise of Modernity: Small Time Agents in a Global Arena

1. Aufl., 2013

Link zum Volltext

Verfügbarkeit prüfen

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators

Journal of cardiac failure, 1998-03, Vol.4 (1), p.3-8

1998

Link zum Volltext

Verfügbarkeit prüfen

Do all heart failure patients benefit from high dose lisinopril? Results from the ATLAS study

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, Vol.35 (2), p.203A

2000

Link zum Volltext

Verfügbarkeit prüfen

Excellent tolerability of high doses of lisinopril in the ATLAS trial

CIRCULATION, 1998, Vol.98 (17), p.82

1998

Link zum Volltext

Verfügbarkeit prüfen

Health economic benefits of treating patients with heart failure with high dose lisinopril versus low dose: The ATLAS study

CIRCULATION, 1998, Vol.98 (17), p.135

1998

Link zum Volltext

Verfügbarkeit prüfen

Analyses of CCD images of nucleon-silicon interaction events

Proceedings of the 7th European Conference on Radiation and Its Effects on Components and Systems, 2003. RADECS 2003, 2003, p.377-383

2003

Link zum Volltext
IEEE_Xplore

Menü

Weitere Dienste

Einstellungen

Mechanisms of Anesthetic Action and Neurotoxicity: Lessons from Molluscs

A novel bio-mimicking, planar nano-edge microelectrode enables enhanced long-term neural recording

The mitochondrial division inhibitor Mdivi-1 rescues mammalian neurons from anesthetic-induced cytotoxicity

General anesthetics and cytotoxicity: possible implications for brain health

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic Heart failure

Acute coronary findings at autopsy in heart failure patients with sudden death : Results from the assessment of treatment with lisinopril and survival (ATLAS) trial

Corrections needed to 2016 ESC and AHA guidelines on heart failure

Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

Analyses of CCD images of nucleon-silicon interaction events

Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study

Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial

Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group

Myocardial infarction redefined : A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

Scandinavian Colonialism and the Rise of Modernity: Small Time Agents in a Global Arena

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators

Do all heart failure patients benefit from high dose lisinopril? Results from the ATLAS study

Excellent tolerability of high doses of lisinopril in the ATLAS trial

Health economic benefits of treating patients with heart failure with high dose lisinopril versus low dose: The ATLAS study

Analyses of CCD images of nucleon-silicon interaction events

Suchergebnisse filtern